3M is a diversified technology company with a worldwide presence in the following markets: consumer and office; display and graphics; electro and communications; health care; industrial; safety, security and protection services; and transportation. 3M is a global enterprise characterised by substantial inter-company cooperation in research, manufacturing and marketing of products. 3M help health care professionals improve the quality of health care throughout the world everyday. 3M's innovative products and services also help increase efficiency in the delivery of patient care. 3M successfully compete in multiple market segments, including medical and surgical products, pharmaceuticals, dental and orthodontic products, health information systems, and personal care products.

55pharma is a small-cap pharmaceutical company that identifies and develops ethical drugs with novel mechanisms of action. After early-stage clinical trials, we sell our drug leads to big pharmaceutical companies. Our unique, high-value discovery approach is designed to result in a significantly shortened lead-to-man development process. Aiming at diseases of multicausal pathogenesis like diabetes, we reverse order in preclinical research: in-vivo lead candidate identification first, mechanism-of-action elucidation in parallel to pre-clinical and early clinical development.

A.P. Pharma, Inc. (NASDAQ: APPA) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company's primary focus is on its lead product candidate, APF530, which has completed a pivotal Phase 3 clinical trial for the prevention of CINV. The NDA was submitted in May 2009 and the FDA has set a Prescription Drug User Fee Act (PDUFA) action date of March 18, 2010.  The Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems.